LINCOLN
FAIRLY_VALUEDLincoln Pharmaceuticals Limited
Pharma · NSE
↑ 49.9% vs fair value
52W Low
₹440
+30.2% from low
52W High
₹677
-15.4% from high
Valuation Gauge
Current Price
₹573
Fair Value
₹1,143
Fair Value Analysis
₹1,143
Based on free cash flow projections and earnings growth potential for Pharma sector companies | Sector-cheap: P/E at 10th percentile vs sector peers. | CAUTION: ROCE declining (latest 15.2%) — returns on capital are falling; verify this isn't a value trap.
Cash Flow Analysis
38% weight
Growth Valuation
63% weight
Price vs Market
Shareholding Pattern
Stock Health Score
Financially Healthy
Profitability
ROE of 13.1% is acceptable for Pharma sector (benchmark: 18%)
Debt & Leverage
D/E ratio of 0.0x is well within the Pharma sector norm of 0.8x — strong balance sheet
Valuation vs Peers
P/E of 13.1x trades at a 69% discount to Pharma sector median (42x) — attractively valued
Cash Flow
FCF margin of 11.8% — strong cash generation (₹74 Cr)
Earnings Growth
5yr EPS CAGR of 5.9% is well below Pharma sector average of 15.3%
Dividend
Dividend yield of 0.3% is symbolic — low but positive
Sentiment Trend — Last 30 Days
Historical Returns
Key Financials
EPS (TTM)
₹46.8
P/E Ratio
13.1x
P/B Ratio
1.7x
ROE
13.1%
ROCE
16.1%
Debt / Equity
0x
Beta
0.36
Div Yield
0.3%
FCF (Cr)
₹74 Cr
Revenue (Cr)
₹623 Cr
EPS Growth 5Y
5.9%
Mkt Cap (Cr)
₹1,212 Cr
52W High
₹677
52W Low
₹440
Book Value/Share
₹352.6
Financial History
Annual P&L data not available yet.
Institutional Activity
Bulk deals, block deals, short selling & delivery volume — NSE data
Insider Trading
Community Pulse
Company Documents
Annual reports, concall transcripts & regulatory filings
Share this Stock
Download card · Share on WhatsApp
Share on WhatsApp, Twitter, or any group — each share brings new users to Veritas Quant